Tyra Biosciences financials
$21.98+2.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Net income | -$119.9M | -$86.5M | -$69.1M | -$55.3M | -$26.3M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.01 | $-1.51 | $-1.62 | $-1.32 | $-1.91 |
| EBITDA | -$132.2M | -$103.7M | -$79.6M | -$58.6M | -$26.1M |
| Operating cash flow | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
| Diluted shares | 59.6M | 57.2M | 42.7M | 41.9M | 13.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $77.4M | $92.0M | $58.0M | $251.2M | $302.2M |
| Short-term investments | $178.6M | $249.5M | $145.5M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M |
| Shareholders' equity | $259.2M | $343.2M | $204.3M | $257.8M | $301.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology